Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$39.76
HK$0.26(1.60%)
At close: 4:00 PM EST
HK$39.76
HK$0.26(1.60%)
Day’s Range― - ―
52-Week RangeHK$26.25 - HK$44.22
Previous CloseN/A
Volume4.63M
Average Volume (3M)9.67M
Market Cap
HK$188.11B
Enterprise ValueHK$161.34B
Total Cash (Recent Filing)HK$31.58B
Total Debt (Recent Filing)HK$105.14M
Price to Earnings (P/E)28.3
Beta0.52
Next Earnings
Aug 20, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.65Price Target Upside17.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$16.93B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityExceptionally high gross and net margins reflect strong pricing power and branded-product mix in core therapeutic areas. Durable margins support reinvestment in R&D, sustain returns on equity, and provide buffer versus cost pressure, underpinning long-term earnings quality.
Very Low LeverageExtremely low leverage delivers financial flexibility to fund R&D, launches, and selective M&A without material refinancing risk. A conservative balance sheet improves resilience to revenue cycles and supports stable capital allocation over the medium term.
Strong Cash GenerationOperating cash flow comfortably exceeding net income and robust free cash flow alignment with earnings indicate high earnings quality. Reliable cash generation enables sustained investment in pipeline commercialization and supports capital returns or strategic initiatives.
Bears Say
Earnings & Cash VolatilityMaterial swings in margins and operating cash conversion impair predictability of free cash flow and make budgeting for R&D and commercialization harder. Such volatility can stem from tender cycles, working-capital swings, or timing of milestone receipts and may recur.
Historical Leverage VariabilityPast episodes of significantly higher leverage show management has used debt cyclically, which could reappear for acquisitions or financing. Episodic leverage increases would reduce financial flexibility and could pressure credit metrics if earnings weaken.
Concentration & Reimbursement RiskHeavy dependence on the Mainland China market and on procurement/reimbursement cycles exposes revenue to policy, pricing, and tendering shifts. Regulatory or reimbursement changes have lasting impact on volume and pricing, limiting geographic diversification benefits.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$26.25 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$188.11B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 20, 2026 which is in 76 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 29, 2026. The company reported HK$0.461 earnings per share for the quarter, beating the consensus estimate of HK$0.392 by HK$0.069.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Quarterly dividend of HK$0.232 which represents an annual dividend yield of 0.97%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.56.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.461 in its last earnings report, beating expectations of HK$0.392. Following the earnings report the stock price went down -0.648%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$46.65 (17.33% Upside)
HK$46.65 (17.33% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.01%
12-Months-Change
Fundamentals
Return on Equity
16.71%
Trailing 12-Months
Asset Growth
31.91%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$46.65
▲(17.33% Upside)
Technical Analysis
HUTCHMED (China)
―
China Medical System Holdings
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---